13 completed, 1 terminated, 1 unknown, 1 withdrawn. 6 Phase 4, 5 Phase 3, 3 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 5 | Completed 4, Unknown 1 |
| Phase 2 | 3 | Completed 3 |
| Not applicable | 1 | Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow ADVAIR DISKUS: new trials by email Literature Review of ADVAIR DISKUS trials Research Report on ADVAIR DISKUS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg, ADVAIR DISKUS - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2018-11-20 | 2018-12-28 |
| A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK, Placebo - Asthma | Phase 3 | Completed | Respirent Pharmaceuticals Co Ltd. | 451 | 2018-10-02 | 2020-07-07 |
| A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50 Test Product, Reference Product, Placebo - Asthma | Phase 3 | Unknown | Amneal Ireland Limited | 1204 | 2018-10-01 | 2018-06-20 |
| Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD) Nebulizers, Dry Powder Inhaler, Brovana - COPD, COPD Exacerbation | Phase 4 | Terminated | Wake Forest University Health Sciences | 40 | 2017-10-03 | 2021-06-22 |
| Environmental Control as Add-on Therapy in Childhood Asthma Flovent Diskus, Home Environmental Intervention, Advair Diskus - Asthma | Phase 2 | Completed | Johns Hopkins University | 155 | 2014-10-01 | 2019-11-20 |
| Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma Fp MDPI, FS MDPI, FLOVENT HFA - Persistent Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 758 | 2014-07-01 | 2021-11-09 |
| Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial fluticasone/salmeterol 250/50 Dry Powder Inhaler, fluticasone/salmeterol 100/50 Dry Powder Inhaler, fluticasone 100mcg Dry Powder Inhaler - Asthma | Phase 4 | Completed | Nemours Children's Clinic | 108 | 2013-10-01 | 2018-12-19 |
| Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects Fp MDPI, FS MDPI, Advair Diskus - Asthma | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 72 | 2013-01-01 | 2017-06-12 |
| The Effect on Depressive Symptoms in ECF Residents With COPD Advair diskus - Chronic Obstructive Pulmonary Disease, Depression | Phase 4 | Completed | Valley Medical Research | 30 | 2009-10-01 | 2016-12-28 |
| Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg - Asthma | Phase 2 | Completed | Sandoz | 105 | 2009-06-01 | 2017-03-29 |
| The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD salmeterol-fluticasone - Chronic Obstructive Pulmonary Disease, Sleep Disorders | Not applicable | Withdrawn | Northwestern University | 2008-08-01 | 2015-10-06 | |
| A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS ADVAIR HFA, ADVAIR DISKUS - Asthma | Phase 4 | Completed | GlaxoSmithKline | 28 | 2006-10-01 | 2016-10-28 |
| Non-invasive Measures of Distal Lung Disease in Asthmatics QVAR, Advair, Servent Diskus - Asthma | Phase 4 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 34 | 2005-09-30 | 2021-12-02 |
| Study Of Allergic Rhinitis In Patients Who Also Have Asthma fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP) - Asthma | Phase 4 | Completed | GlaxoSmithKline | 725 | 2005-09-01 | 2016-12-16 |
| Symbicort Onset of Action 1 budesonide/formoterol (Symbicort), fluticasone/salmeterol (Advair Diskus), albuterol (Ventolin) - Asthma | Phase 3 | Completed | AstraZeneca | 48 | 2003-04-01 | 2009-04-06 |
| Symbicort Onset of Action 2 budesonide/formoterol, fluticasone/salmeterol, albuterol - Asthma | Phase 3 | Completed | AstraZeneca | 48 | 2003-03-01 | 2011-01-24 |
Asthma (11) · Pulmonary Disease, Chronic Obstructive (3) · Depression (1) · Rhinitis, Allergic (1) · Sleep Initiation and Maintenance Disorders (1) · Sleep Wake Disorders (1)
Teva Branded Pharmaceutical Products R&D, Inc. (3) · AstraZeneca (2) · GlaxoSmithKline (2) · Respirent Pharmaceuticals Co Ltd. (2) · Amneal Ireland Limited (1) · Johns Hopkins University (1) · Nemours Children's Clinic (1) · Northwestern University (1) · Sandoz (1) · Valley Medical Research (1) · Wake Forest University Health Sciences (1)
United States (11) · Greece (2) · Canada (1) · Estonia (1) · Poland (1)
Catherine Bonuccelli (2) · Athanasios Konstantinidis, Ass.Professor (1) · Chrysoula Doxani, MD, MSc, PhD (1) · Corinne Keet, MD PHD (1) · Elizabeth C Matsui, MD MHS (1) · Ioannis Stefanidis, Professor (1) · Irshad Haque (1) · Jill A Ohar, MD, FCCP (1) · Kathryn Blake, PharmD (1) · Meenakshi Patel, MD (1) · Meredith McCormack, MD MHS (1) · Michelle Zeidler, MD (1) · Ravi Kalhan, MD, MS (1)
PMID 20167147, PMID 27216137, PMID 28540844, PMID 36472162, PMID 37347518
R01HL114899 (1)